Generate text that refutes this claim: When generic drugs are legalized firms and individuals no longer feel the incentive to misallocate resources to the race to patent new drugs and to monitor existing patents, or to spend resources stealing from one another  Patent regimes cause firms to inefficiently allocate resources. One such inefficiency arises from the duplication of effort by firms seeking to develop the same or very similar drugs, though only the first to do so may profit from it due to the winner-takes-all patent system. This leads to brutal races and excessive expenditure of resources to be first over the line and to monopolize the production, at least for a time. These races can thus lead to efforts by firms to steal research from one another, thus resulting in further wastes of resources in engaging and attempting to prevent corporate espionage. Another serious inefficiency arises in the production of similar products to existing ones, seeking to get around existing patents. Such has been the case for years in the pharmaceutical industry, which has succeeded, for example, in curing erectile dysfunction dozens of times. An overemphasis on such spinning off of similar products is the result of patent-generated inefficiency 1. The inefficiency does not end with production, however, as firms likewise devote great amounts of resources and effort to the development of non-duplicable products, in monitoring for infringement, and in prosecuting offenders, all of which generates huge costs and little or no return 2. Furthermore, the deterrent effect to patent piracy generated by all the efforts of the state and firms has proven generally minimal. Clearly, in the absence of patent protection for pharmaceuticals, markets and firms will behave more efficiently. This is shown by the introduction of generic antiretroviral drugs for treating AIDS where the introduction of generic drugs forced the price of the branded drugs down from $10439 to $931 in September/October 2000 3.  1 Gabb, Sean. 2005. "Market Failure and the Pharmaceutical Industry: A Proposal for Reform". National Health Federation. Available: 2 World Intellectual Property Organization. 2011. "Emerging Issues in Intellectual Property". Available: 3 Avert.org, "AIDS, Drug Prices and Generic Drugs",
disease health general house would allow production generic drugs
The costs associated with the current patent regime are necessary to the maintenance of innovation. It may be costly, and technically inefficient to police property rights, but that does not make them less of a right. If firms feel they can benefit from fighting infringers of their patent rights, it is their right to do so. The state likewise, has an obligation to protect the rights, physical and intangible, of its citizens and cannot give up on them simply because they prove difficult and costly to enforce.